Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Although the pharmaceutical-related business was affected by the NHI drug price revision, new drugs grew mainly. In the healthcare business, revenue from Collage Furfur and Collage Repair products increased. Operating profit increased due to higher gross profit accompanying the increase in revenue from the pharmaceutical-related business, while ordinary income increased due mainly to the recognition of an equity-method investment gain related to アンドファーマ株式会社.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | 31,719 Millions of yen (YoY +19.1%) |
| Operating profit | 3,564 Millions of yen (YoY +38.5%) |
| Ordinary income | 4,187 Millions of yen (YoY +50.5%) |
| Profit attributable to owners of the parent | 3,178 Millions of yen (YoY +67.8%) |
| Total assets | 181,422 Millions of yen |
| Net assets | 140,293 Millions of yen |
| Revision to Earnings Forecast | No revision |
| Depreciation and amortization | 730 Millions of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities 687 Millions of yen / Extraordinary loss Loss on disposal and sale of non-current assets 0 Millions of yen, Costs of removing non-current assets 9 Millions of yen |
| Disclosure regarding the going concern assumption | Not applicable. |
| Factors Behind Changes in Business Performance | Although the pharmaceutical-related business was affected by the NHI drug price revision, new drugs grew mainly. In the healthcare business, revenue from Collage Furfur and Collage Repair products increased. Operating profit increased due to higher gross profit accompanying the increase in revenue from the pharmaceutical-related business, while ordinary income increased due mainly to the recognition of an equity-method investment gain related to アンドファーマ株式会社. |
Items this document does not state (23)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from the pharmaceutical-related business increased, mainly due to growth in new drugs, resulting in higher gross profit and operating profit. Ordinary income increased due mainly to the recognition of an equity-method investment gain related to アンドファーマ株式会社. In the healthcare business, revenue from Collage Furfur and Collage Repair products increased.